Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349

被引：41

作者：

Pei, Zhonghua ^{[1
]}

Blackwood, Elizabeth ^{[2
]}

Liu, Lichuan ^{[3
]}

Malek, Shiva ^{[4
]}

Belvin, Marcia ^{[2
]}

Koehler, Michael F. T. ^{[1
]}

Ortwine, Daniel F. ^{[1
]}

Chen, Huifen ^{[1
]}

Cohen, Frederick ^{[1
]}

Kenny, Jane R. ^{[3
]}

Bergeron, Philippe ^{[1
]}

Lau, Kevin ^{[1
]}

Ly, Cuong ^{[1
]}

Zhao, Xianrui ^{[1
]}

Estrada, Anthony A. ^{[1
]}

Tom Truong ^{[2
]}

Epler, Jennifer A. ^{[2
]}

Nonomiya, Jim ^{[4
]}

Lan Trinh ^{[4
]}

Sideris, Steve ^{[4
]}

Lesnick, John ^{[4
]}

Bao, Linda ^{[5
]}

Vijapurkar, Ulka ^{[2
]}

Mukadam, Sophie ^{[3
]}

Tay, Suzanne ^{[3
]}

Deshmukh, Gauri ^{[3
]}

Chen, Yung-Hsiang ^{[3
]}

Ding, Xiao ^{[3
]}

Friedman, Lori S. ^{[2
]}

Lyssikatos, Joseph P. ^{[1
]}

机构：

[1] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA

[2] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA

[3] Genentech Inc, Dept DMPK, San Francisco, CA 94080 USA

[4] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA

[5] Genentech Inc, Dept Pharmaceut, San Francisco, CA 94080 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 01期

关键词：

Mammalian target of rapamycin; mTOR; TDI; urea bioisostere; MECHANISM-BASED INACTIVATION; CYTOCHROME-P450; ENZYMES; GDC-0941; CANCER; KINASE;

D O I：

10.1021/ml3003132

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.

引用

页码：103 / 107

页数：5

共 19 条

[1] Ligand structural aspects of hERG channel blockade
Aronov, Alex M.
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1113 - 1127
[2] Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, Don
Colombi, Marco
Moroni, Christoph
Hall, Michael N.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) : 868 - 880
[3] The phosphoinositide 3-kinase pathway
Cantley, LC
[J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
[4] Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine
Cohen, Frederick
Bergeron, Philippe
Blackwood, Elizabeth
Bowman, Krista K.
Chen, Huifen
DiPasquale, Antonio G.
Epler, Jennifer A.
Koehler, Michael F. T.
Lau, Kevin
Lewis, Cristina
Liu, Lichuan
Ly, Cuong Q.
Malek, Shiva
Nonomiya, Jim
Ortwine, Daniel F.
Pei, Zhonghua
Robarge, Kirk D.
Sideris, Steve
Trinh, Lan
Truong, Tom
Wu, Jiansheng
Zhao, Xianrui
Lyssikatos, Joseph P.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) : 3426 - 3435
[5] Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
Crew, Andrew P.
Bhagwat, Shripad V.
Dong, Hanqing
Bittner, Mark A.
Chan, Anna
Chen, Xin
Coate, Heather
Cooke, Andrew
Gokhale, Prafulla C.
Honda, Ayako
Jin, Meizhong
Kahler, Jennifer
Mantis, Christine
Mulvihill, Mark J.
Tavares-Greco, Paula A.
Volk, Brian
Wang, Jing
Werner, Douglas S.
Arnold, Lee D.
Pachter, Jonathan A.
Wild, Robert
Gibson, Neil W.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (07) : 2092 - 2097
[6] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Folkes, Adrian J.
Ahmadi, Khatereh
Alderton, Wendy K.
Alix, Sonia
Baker, Stewart J.
Box, Gary
Chuckowree, Irina S.
Clarke, Paul A.
Depledge, Paul
Eccles, Suzanne A.
Friedman, Lori S.
Hayes, Angela
Hancox, Timothy C.
Kugendradas, Arumugam
Lensun, Letitia
Moore, Pauline
Olivero, Alan G.
Pang, Jodie
Patel, Sonal
Pergl-Wilson, Giles H.
Raynaud, Florence I.
Robson, Anthony
Saghir, Nahid
Salphati, Laurent
Sohal, Sukhjit
Ultsch, Mark H.
Valenti, Melanie
Wallweber, Heidi J. A.
Wan, Nan Chi
Wiesmann, Christian
Workman, Paul
Zhyvoloup, Alexander
Zvelebil, Marketa J.
Shuttleworth, Stephen J.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) : 5522 - 5532
[7] Defining the role of mTOR in cancer
Guertin, David A.
Sabatini, David M.
[J]. CANCER CELL, 2007, 12 (01) : 9 - 22
[8] Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Hoeflich, Klaus P.
Merchant, Mark
Orr, Christine
Chan, Jocelyn
Den Otter, Doug
Berry, Leanne
Kasman, Ian
Koeppen, Hartmut
Rice, Ken
Yang, Nai-Ying
Engst, Stefan
Johnston, Stuart
Friedman, Lori S.
Belvin, Marcia
[J]. CANCER RESEARCH, 2012, 72 (01) : 210 - 219
[9] Kalgutkar AS, 2007, CURR DRUG METAB, V8, P407
[10] Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4
Kalgutkar, AS
Vaz, ADN
Lame, ME
Henne, KR
Soglia, J
Zhao, SX
Abramov, YA
Lombardo, F
Collin, C
Hendsch, ZS
Hop, CECA
[J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (02) : 243 - 253

← 1 2 →